The next-generation checkpoint pipeline expands, slowly

Breakthrough data from next-generation checkpoint inhibitors have been scarce, and the rate of growth in industry’s checkpoint pipeline has slowed, but that doesn’t mean growth has stopped. The majority of checkpoint targets tracked by BioCentury continue to see a net increase in the number of programs against them. 

Moreover, momentum could return to the target class after the positive readouts that kicked off the 2023 American Society of Clinical Oncology (ASCO) conference brought fresh optimism to the field. ...